Clinical Trial Update: Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

This update describes a Phase 2 trial evaluating Rituxan plus FavId idiotype vaccine for low-grade non-Hodgkin lymphoma. The current status of the trial is UNKN…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• FavId (idiotype vaccine)
• Rituxan (rituximab)

Snippet

Sponsor: Favrille | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: UNKNOWN